BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800-806. [PMID: 32504663 DOI: 10.1016/j.jhep.2020.05.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Reference Citation Analysis]
2 Diao Y, Hu D, Hu X, Wang P, Wang X, Luo X, Wang H, Ning Q. The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase. Infect Dis Ther. [DOI: 10.1007/s40121-022-00629-5] [Reference Citation Analysis]
3 Yu MW, Lin CL, Liu CJ, Huang YW, Hu JT, Wu WJ, Wu CF. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc 2021:S0929-6646(21)00486-1. [PMID: 34764005 DOI: 10.1016/j.jfma.2021.10.014] [Reference Citation Analysis]
4 Qu S, Zhang X, Wu Y, Li H, Zhai J, Wu D. miR-361-3p Regulates Liver Tumor-initiating Cells Expansion and Chemo-resistance. J Cancer 2021;12:1483-92. [PMID: 33531993 DOI: 10.7150/jca.52395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T. Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel) 2021;13:1949. [PMID: 33919570 DOI: 10.3390/cancers13081949] [Reference Citation Analysis]
6 Inoue J, Kobayashi T, Akahane T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Niitsuma H, Masamune A; THERME Study Group. Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study. JCM 2022;11:2354. [DOI: 10.3390/jcm11092354] [Reference Citation Analysis]
7 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, Cheung KS, Yuen MF, Seto WK. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int 2021;15:901-11. [PMID: 34152534 DOI: 10.1007/s12072-021-10218-2] [Reference Citation Analysis]
8 Chen Q, Zhao L, Mei L, Zhong R, Han P, Yang H, Li Q, Li J. Association of sex hormones with hepatic steatosis in men with chronic hepatitis B. Dig Liver Dis 2021:S1590-8658(21)00273-5. [PMID: 34116975 DOI: 10.1016/j.dld.2021.05.022] [Reference Citation Analysis]
9 Mak LY, Wong DK, Cheung KS, Hui RW, Liu F, Fung J, Seto WK, Yuen MF. Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection. Dig Dis Sci 2022. [PMID: 35258755 DOI: 10.1007/s10620-022-07429-4] [Reference Citation Analysis]
10 Fan R, Hou J. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply. Aliment Pharmacol Ther 2021;54:724-5. [PMID: 34379840 DOI: 10.1111/apt.16548] [Reference Citation Analysis]
11 Fan R, Niu J, Ma H, Xie Q, Cheng J, Rao H, Dou X, Xie J, Zhao W, Peng J, Gao Z, Gao H, Chen X, Chen J, Li Q, Tang H, Zhang Z, Ren H, Cheng M, Liang X, Zhu C, Wei L, Jia J, Sun J, Hou J; Chronic Hepatitis B Study Consortium. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther 2021;54:329-38. [PMID: 34157146 DOI: 10.1111/apt.16469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hui RW, Chan AC, Lo G, Lo R, Chan C, Kotewall CN, Mak L, She W, Au K, Ai V, Fung J, Yuen M, Seto W. Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. Hepatol Int. [DOI: 10.1007/s12072-022-10305-y] [Reference Citation Analysis]
13 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. J Viral Hepat 2021. [PMID: 34382730 DOI: 10.1111/jvh.13594] [Reference Citation Analysis]
14 Chang XJ, Shi YW, Wang J, Liu HB, Chen Y, Zhu XN, Chen YP, Yu ZJ, Shang QH, Tan L, Li Q, Jiang L, Xiao GM, Chen L, Lu W, Hu XY, Long QH, An LJ, Zou ZY, Wong VW, Yang YP, Fan JG. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00122-3. [PMID: 34275749 DOI: 10.1016/j.hbpd.2021.06.009] [Reference Citation Analysis]
15 Oh JH, Lee HW, Sinn DH, Park JY, Kim BK, Kim SU, Kim DY, Ahn SH, Kang W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Paik YH. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int 2021;15:892-900. [PMID: 34260013 DOI: 10.1007/s12072-021-10205-7] [Reference Citation Analysis]
16 Mak L, Yuen M, Seto W. Letter regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”. Journal of Hepatology 2020;73:1573-4. [DOI: 10.1016/j.jhep.2020.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
17 Cheung KS, Mak LY, Lam LK, Fung J, Liu F, Seto WK, Yuen MF. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatol Int 2021;15:881-91. [PMID: 33988834 DOI: 10.1007/s12072-021-10197-4] [Reference Citation Analysis]
18 van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ, Sonneveld MJ. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep 2021;3:100350. [PMID: 34557660 DOI: 10.1016/j.jhepr.2021.100350] [Reference Citation Analysis]
19 Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol 2021; 27(26): 3971-3983 [PMID: 34326608 DOI: 10.3748/wjg.v27.i26.3971] [Reference Citation Analysis]
20 Con D, Clayton-Chubb D, Lubel J, Sawhney R, Bloom S. Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver disease. J Hepatol 2021;75:236-8. [PMID: 33617924 DOI: 10.1016/j.jhep.2021.02.013] [Reference Citation Analysis]
21 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]